MX379440B - Moduladores de canales de ca2+ activados de liberación de ca2+ (crac) y usos farmacéuticos de los mismos. - Google Patents
Moduladores de canales de ca2+ activados de liberación de ca2+ (crac) y usos farmacéuticos de los mismos.Info
- Publication number
- MX379440B MX379440B MX2017009164A MX2017009164A MX379440B MX 379440 B MX379440 B MX 379440B MX 2017009164 A MX2017009164 A MX 2017009164A MX 2017009164 A MX2017009164 A MX 2017009164A MX 379440 B MX379440 B MX 379440B
- Authority
- MX
- Mexico
- Prior art keywords
- sup
- crac
- channels
- modulators
- activated
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 abstract 4
- 102000020167 Calcium release-activated calcium channel Human genes 0.000 abstract 2
- 108091022898 Calcium release-activated calcium channel Proteins 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 201000010099 disease Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D207/32—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D207/33—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms with substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D207/32—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D207/33—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms with substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D207/333—Radicals substituted by oxygen or sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Gastroenterology & Hepatology (AREA)
- Oncology (AREA)
- Urology & Nephrology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyrrole Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562103033P | 2015-01-13 | 2015-01-13 | |
| PCT/US2016/012909 WO2016115054A2 (en) | 2015-01-13 | 2016-01-11 | Modulators of ca2+ release-activated ca2+ (crac) channels and pharmaceutical uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2017009164A MX2017009164A (es) | 2018-03-06 |
| MX379440B true MX379440B (es) | 2025-03-11 |
Family
ID=56406559
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2017009164A MX379440B (es) | 2015-01-13 | 2016-01-11 | Moduladores de canales de ca2+ activados de liberación de ca2+ (crac) y usos farmacéuticos de los mismos. |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US10213412B2 (https=) |
| EP (1) | EP3245189B1 (https=) |
| JP (1) | JP6764866B2 (https=) |
| CN (1) | CN107207431B (https=) |
| AU (1) | AU2016207014B2 (https=) |
| CA (1) | CA2969814C (https=) |
| ES (1) | ES2825798T3 (https=) |
| MX (1) | MX379440B (https=) |
| WO (1) | WO2016115054A2 (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2825798T3 (es) | 2015-01-13 | 2021-05-17 | Vivreon Biosciences Llc | Moduladores de canales de Ca2+ activados por liberación de Ca2+ (CRAC) y usos farmacéuticos de los mismos |
| US20200237743A1 (en) * | 2017-10-17 | 2020-07-30 | Rhizen Pharmaceuticals Sa | Crac channel modulators for treating esophageal cancer |
| AU2018360367A1 (en) * | 2017-10-30 | 2020-05-28 | Rhizen Pharmaceuticals Sa | Calcium release-activated calcium channel modulators for treating hematological and solid cancers |
| SG11202102491RA (en) | 2018-09-14 | 2021-04-29 | Rhizen Pharmaceuticals A G | Compositions comprising a crac inhibitor and a corticosteroid and methods of use thereof |
| PH12022552447A1 (en) * | 2020-03-16 | 2024-01-03 | Zomagen Biosciences Ltd | Nlrp3 modulators |
| JP2023526505A (ja) * | 2020-05-20 | 2023-06-21 | カルシメディカ，インク． | 急性腎障害を治療するための方法および組成物 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4644009A (en) * | 1984-10-29 | 1987-02-17 | Usv Pharmaceutical Corporation | Aryl-alkyl heterocyclic compounds |
| US5041442A (en) * | 1990-07-31 | 1991-08-20 | Syntex (U.S.A.) Inc. | Pyrrolo(1,2-a)pyrazines as inhibitors of gastric acid secretion |
| BR9306040A (pt) | 1992-03-06 | 1997-11-18 | Statens Seruminstitut | Tratamento e profilaxia de doenças provocadas por parasitos ou bactérias |
| ES2185693T3 (es) * | 1994-01-19 | 2003-05-01 | Sankyo Co | Derivado de pirrolopiridacina. |
| JP3143571B2 (ja) * | 1994-01-19 | 2001-03-07 | 三共株式会社 | ピロロピリダジン誘導体 |
| JP2000256358A (ja) * | 1999-03-10 | 2000-09-19 | Yamanouchi Pharmaceut Co Ltd | ピラゾール誘導体 |
| CN101083985A (zh) * | 2004-09-21 | 2007-12-05 | 幸讬制药公司 | 用于炎症及免疫相关用途的化合物 |
| EP1896446A1 (en) * | 2005-06-24 | 2008-03-12 | Actelion Pharmaceuticals Ltd. | Novel thiophene derivatives |
| US8377970B2 (en) * | 2009-10-08 | 2013-02-19 | Rhizen Pharmaceuticals Sa | Modulators of calcium release-activated calcium channel |
| US8993612B2 (en) * | 2009-10-08 | 2015-03-31 | Rhizen Pharmaceuticals Sa | Modulators of calcium release-activated calcium channel and methods for treatment of non-small cell lung cancer |
| TW201130488A (en) * | 2010-02-03 | 2011-09-16 | Daiichi Sankyo Co Ltd | Pyrrole compound |
| ES2602140T3 (es) * | 2011-06-27 | 2017-02-17 | Newron Pharmaceuticals S.P.A. | Derivados de arilalquilaminocarboxamida fluorados |
| AU2014282886A1 (en) * | 2013-06-17 | 2015-12-17 | Lupin Limited | Pyrrole derivatives as alpha 7 nAChR modulators |
| ES2825798T3 (es) | 2015-01-13 | 2021-05-17 | Vivreon Biosciences Llc | Moduladores de canales de Ca2+ activados por liberación de Ca2+ (CRAC) y usos farmacéuticos de los mismos |
-
2016
- 2016-01-11 ES ES16737683T patent/ES2825798T3/es active Active
- 2016-01-11 US US15/539,088 patent/US10213412B2/en active Active
- 2016-01-11 EP EP16737683.9A patent/EP3245189B1/en not_active Not-in-force
- 2016-01-11 CN CN201680005731.2A patent/CN107207431B/zh not_active Expired - Fee Related
- 2016-01-11 AU AU2016207014A patent/AU2016207014B2/en not_active Ceased
- 2016-01-11 WO PCT/US2016/012909 patent/WO2016115054A2/en not_active Ceased
- 2016-01-11 CA CA2969814A patent/CA2969814C/en active Active
- 2016-01-11 MX MX2017009164A patent/MX379440B/es unknown
- 2016-01-11 JP JP2017533635A patent/JP6764866B2/ja not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| HK1245797A1 (en) | 2018-08-31 |
| EP3245189A2 (en) | 2017-11-22 |
| CN107207431A (zh) | 2017-09-26 |
| WO2016115054A3 (en) | 2016-09-01 |
| CA2969814C (en) | 2023-06-13 |
| EP3245189A4 (en) | 2018-07-18 |
| US10213412B2 (en) | 2019-02-26 |
| JP2018502083A (ja) | 2018-01-25 |
| CA2969814A1 (en) | 2016-07-21 |
| AU2016207014B2 (en) | 2020-07-16 |
| JP6764866B2 (ja) | 2020-10-07 |
| CN107207431B (zh) | 2021-02-09 |
| US20180263960A1 (en) | 2018-09-20 |
| EP3245189B1 (en) | 2020-07-22 |
| MX2017009164A (es) | 2018-03-06 |
| WO2016115054A2 (en) | 2016-07-21 |
| AU2016207014A1 (en) | 2017-07-06 |
| ES2825798T3 (es) | 2021-05-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12020500066A1 (en) | Carboxamides as modulators of sodium channels | |
| PH12019502058A1 (en) | Farnesoid x receptor agonists and uses thereof | |
| MX2019010949A (es) | Moduladores de somatostatina y usos de los mismos. | |
| NZ750174A (en) | Somatostatin modulators and uses thereof | |
| PH12018500586A1 (en) | Farnesoid x receptor agonists and uses thereof | |
| MX2022001755A (es) | Compuestos de dinucleotidos ciclicos y metodos de uso. | |
| PH12022550359A1 (en) | Nonpeptide somatostatin type 5 receptor agonists and uses thereof | |
| PH12019502646A1 (en) | Pyrazole magl inhibitors | |
| PH12020500371A1 (en) | Spirocycle compounds and methods of making and using same | |
| PH12015501740A1 (en) | Sodium channel modulators for the treatment of pain | |
| MX2018009752A (es) | 1,2,3,-triazoles sustituidos como moduladores de nmda selectivos de nr2b. | |
| PH12016500432A1 (en) | Inhibitors of erk and methods of use | |
| HK1255034A1 (zh) | 生长抑素调节剂及其用途 | |
| MX2017011997A (es) | Carbamatos de piperacina y metodos de preparacion y uso. | |
| MX379811B (es) | Citocinas quimiotácticas como moduladores de los receptores ccr2 y el uso de las mismas en el tratamiento de enfermedades | |
| MX2018000352A (es) | 4-azaindoles sustituidos y su uso como moduladores del receptor glun2b. | |
| PH12020500372A1 (en) | Spirocycle compounds and methods of making and using same | |
| MX2020007586A (es) | Proceso de fabricacion de moduladores de somatostatina. | |
| MX379440B (es) | Moduladores de canales de ca2+ activados de liberación de ca2+ (crac) y usos farmacéuticos de los mismos. | |
| MX2019014042A (es) | Inhibidores pirazolicos de magl. | |
| PH12017500494A1 (en) | Methyl-and trifluoromethyl-substituted pyrrolopyridine modulators of rorc2 and methods of use thereof | |
| MX2022000712A (es) | Moduladores de nlrp3. | |
| EP4424683A3 (en) | Dual magl and faah inhibitors | |
| HK1255074A1 (zh) | 生长抑素调节剂及其用途 | |
| PH12019500949A1 (en) | Ror-gamma modulators |